Venture Fund I

$22M deployed in record time into 14 companies.
Closed
2023 at $22M
Fully Invested

2023

Portfolio  
14 companies
View your LP Investment

Directing More Capital

In late 2022, Plum Alley raised a $22M venture Fund to invest in frontier tech and medical breakthroughs with women founders and gender diverse founding teams. This enabled us to expand our investor base and to give investors the option to have a portfolio of companies with our same investment thesis.  Many of the Fund investments came from the companies that our Plum Alley SPVs had invested in and met the Fund criteria.

Many investors have a mandate to invest in a fund structure and want a portfolio of companies selected by professional managers. Plum Alley Venture Fund I gave investors that option.

GPs of the Fund are Deborah Jackson, Andrea Turner Moffitt and Avantika Daing.

Investment Thesis
We believe frontier technologies and medical breakthroughs have the best chance to bring positive change and address many of our fundamental challenges. We believe in founders that have vision, credentials and a history of success in various endeavors with a distinct and powerful vision for their companies and the future. These are women founders and teams of men and women from many different backgrounds and perspectives.
Our Portfolio Companies Matter
Our firm and investments meet many of the UN Sustainable Development Goals. By only investing in companies with at least one woman founder, we champion Goal 5. Goals 3, 8, 9, 11, and 13 are fundamental to our investment theses in Environment, Human Health, Advanced Systems, and Inclusive Growth. Through our portfolio companies and broader network, we impact all 17 SDGs.

Portfolio

Our Portfolio Companies Matter
Our firm and investments meet many of the UN Sustainable Development Goals. By only investing in companies with at least one woman founder, we champion Goal 5. Goals 3, 8, 9, 11, and 13 are fundamental to our investment theses in Environment, Human Health, Advanced Systems, and Inclusive Growth. Through our portfolio companies and broader network, we impact all 17 SDGs.
Mammoth Biosciences
Mammoth Biosciences is pioneering CRISPR technology. With a distinguished team full of deep technical expertise, including CRISPR co-inventor and Nobel Laureate Dr. Jennifer Doudna, Mammoth is working to permanently cure genetic diseases with one-time in vivo delivery of CRISPR therapeutics. While legacy CRISPR systems exceed payload restrictions, Mammoth Biosciences is creating proprietary next-generation CRISPR systems, which are smaller, have a higher fidelity, greater multiplexing potential, and can enable genome editing results that might not be possible with other Cas systems. Mammoth Biosciences has made significant progress in commercializing its CRISPR platform, including two therapeutic partnerships with major pharma players Bayer and Vertex totaling over 1.6 billion in potential revenue for the Company.
Einride
Einride is the world's first autonomous fully electric freight transportation (AET) solution with commercial operations since April 2018. They are disrupting the supply chain and logistics for multinational corporations in the U.S. and Europe.
AiFi
AiFi has invented a proprietary multimodal platform (leveraging computer vision, artificial intelligence, smart sensors, and edge computing) to provide customers and retailers with an autonomous retail experience. AiFi’s automated retail-as-a-service platform is integrated into the existing retail infrastructure.
InnerPlant
InnerPlant is an advanced sensor seed AgTech platform on a mission to transform farming by enabling crops to communicate with growers, creating a more resilient and sustainable farming system. The Company is creating crops that communicate via signaling through fluorescent proteins produced in their leaves to warn farmers of stress caused by fungi, drought, pests, diseases, and nutrient deficiencies. These signaling proteins convert plants into living sensors that provide early signals for various forms of distress experienced by crops.
Gameto
Gameto is a biotechnology company using novel cellular reprogramming technology to solve the problem of accelerated ovarian aging to change the trajectory of women's health and longevity, improving women’s life quality and equality, to empower all the women in the world.
One Health
One Health is bringing individualized precision medicine to canine cancer patients, improving care while generating the world’s largest real-world evidence database for canine cancer genomics and unlocking new translational medicine opportunities for human oncology research and development.
Air Protein
Air Protein is a modern meat-analogue company creating air-based meat and protein-enriched food from a closed loop carbon transformation process. They are positioned to be the most delicious, nutritious, cost effective and sustainable meat alternative with a go to market strategy focused first on chicken, followed by seafood, beef and other products.
Ashvattha
Ashvattha Therapeutics is creating products that selectively target and treat human diseases. Through their patented hydroxyl dendrimer molecules, Ashvattha can target inflammation-causing macrophages without harming the surrounding cells, leading to greater efficacy than traditional free drug applications.
Biobot Analytics
Biobot Analytics is a market-leading wastewater epidemiology platform providing municipality, community, and building-level health data analytics across COVID-19, influenza, opioids and more.
Openwater
Openwater has developed a low-cost, LiDar-based internal body imaging device with the potential to fundamentally change medicine. At the forefront of medical innovation, Openwater's revolutionary new medical imaging modality uses proprietary opto-electronics, holographic systems and novel lasers, rivaling current medical imaging scanners and standard of care at significantly lower costs. Openwater's unique approach to measuring blood flow allows for a wide range of medical applications.
Helaina
Helaina is a food science company defining a new category of consumer immunology by engineering and fermenting yeast to grow human milk proteins bringing the immune-benefits of mothers milk to consumer products, starting with infant formula.
Ketos
KETOS has built a proprietary, first-to-market automated water testing platform that combines an all-in-one, multi-parameter hardware device with an advanced analytics platform capable of measuring quality, quantity and flow of water across industries.
Aclima
Aclima aims to be the first company to provide a cheaper, faster and better way to monitor air quality at the urban scale using its high-resolution data to help governments, cities, enterprises and citizens drive action. Aclima’s proprietary technology is validated by the EPA as meeting scientific measurement standards, and is able to measure all core greenhouse gases and a suite of other air pollutants at a 100-1000X cost reduction from traditional approaches.
Arix Technologies
Arix Technologies is revolutionizing industrial corrosion management for safety and sustainability with a proprietary robotic inspection solution paired with a robust data analytics platform, paving the way for next generation 'smart industry' and a more sustainable future.